Home › Companies › DBVT

DBV Technologies

DBVT Lead: NDA Submitted 5 Biotech Distilled articles ↓

Immunology Protein

Most recent annual filing: 2026-03-15

Pipeline (2 active programs)

Viaskin Peanut

DBV712

Protein

Peanut Allergy NDA Submitted topical

Viaskin Milk

VIASKIN milk patch · DBV135

Protein

Cow's Milk Allergy Phase 1 topical

Technology platforms

Viaskin

Epicutaneous immunotherapy (EPIT) patch delivery platform; designed to re-educate the immune system via skin-based antigen delivery; focus area: food allergies and other immunological diseases including peanut allergy and cow's milk allergy

Discontinued (1)

Viaskin Milk — Eosinophilic Esophagitis

Biotech Distilled coverage (5)

2026-07-17 UPDATE: DBV Technologies (DBVT) - The ATM Refills, One Day After the Warning Letter
2026-07-16 UPDATE: DBV Technologies (DBVT) - The Warning Letter Buried in the 10-Q
2026-06-29 UPDATE: DBV Technologies (DBVT) - The BLA Slips a Quarter
2026-03-28 UPDATE: DBV Technologies (DBVT) - FDA Hits Fast Forward 🔒 Paid
2025-12-22 DBV Technologies (DBVT): Scientific Due Diligence 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.